Skip to main content
SpringerLink
Log in

Linagliptin: a guide to its use in type 2 diabetes mellitus

  • Adis Drug Clinical Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Linagliptin (Trajenta®; Tradjenta™), a dipeptidyl peptidase-4 inhibitor, is indicated for the treatment of type 2 diabetes mellitus. It has a favourable pharmacokinetic profile in terms of its primarily non-renal route of elimination. In clinical trials, oral linagliptin, as monotherapy or in combination with other oral antihyperglycaemic agents, improved glycaemic control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1

Similar content being viewed by others

References

  1. Scott LJ. Linagliptin in type 2 diabetes mellitus. Drugs 2011; 71(5): 611–24

    Article  PubMed  CAS  Google Scholar 

  2. Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Drugs 2011: 7(11): 1441–67

    Article  Google Scholar 

  3. Trajenta®: summary of product characteristics. London: European Medicines Agency, 2011 Oct 6

  4. Tradjenta™ (linagliptin): US prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, Inc., 2011 Jul

  5. Graefe-Mody U, Friedrich C, Port A, et al. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011 Oct; 13(10): 939–46

    Article  PubMed  CAS  Google Scholar 

  6. Graefe-Mody U, Rose P, Retlich S, et al. Pharmacokinetics of linagliptin in subjects with hepatic impairment. Br J Clin Pharmacol. Epub 2012 Jan 13

  7. Graefe-Mody U, Giessmann T, Ring A, et al. A randomized, open-label, crossover study evaluating the effect of food on the relative bioavailability of linagliptin in healthy subjects. Clin Ther 2011 Aug; 33(8): 1096–103

    Article  PubMed  CAS  Google Scholar 

  8. Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2012 Apr; 14(4): 348–57

    Article  PubMed  CAS  Google Scholar 

  9. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomised controlled trial. Diab Obes Metab 2011; 13(3): 258–67

    Article  Google Scholar 

  10. Barnett AH, Harper R, Toorawa R, et al. Linagliptin monotherapy improves glycaemic control in type 2 diabetes patients for whom metformin therapy is inappropriate [abstract no. 823]. Diabetologia 2010; 53 Suppl. 1: S327

    Google Scholar 

  11. Taskinen M, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obesity Metab 2011; 13(1): 65–74

    Article  CAS  Google Scholar 

  12. Gallwitz B, Uhlig-Laske B, Bhattacharaya S, et al. Linagliptin has similar efficacy to glimepiride but improved cardiovascular safety over 2 years in patients with type 2 diabetes inadequately controlled on metformin [abstract no. 39-LB]. 71st Annual Scientific Sessions of the American Diabetes Association; 2011 Jun 25–29; San Diego (CA)

  13. Owens DR, Swallow R, Dugi KA. et al. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011 Nov; 28(11): 1352–61

    Article  PubMed  CAS  Google Scholar 

  14. Schernthaner G, Barnett AH, Emser A, et al. Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes Obes Metab. Epub 2012 Jan 23

  15. Gomis R, Espadero RM, Jones R, et al. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011 Jul; 13(7): 653–61

    Article  PubMed  CAS  Google Scholar 

  16. Lewin AJ, Arvay L, Liu D, et al. Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes [abstract no. 821]. 46th Annual Meeting of the European Association for the Study of Diabetes; 2010 Sep 20–24; Stockholm

  17. Haak T, Meinicke T, Jones R et al. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab. Epub 2012 Feb 22

  18. Johansen OE, Neubacher D, von Eynatten M, et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a prespecified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012 Jan 10; 11: 3

    Article  PubMed  CAS  Google Scholar 

  19. Boehringer Ingelheim Pharmaceuticals. CAROLINA: cardiovascular outcome study of linagliptin versus glimepiride in patients with type 2 diabetes [ClinicalTrials.gov identifier NCT01243424]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2012 Mar 8]

Download references

Acknowledgements and Disclosure

This review was updated from Drugs 2011; 71 (5); 611–24,[1] and reviewed by J. Freeman, Division of Endocrinology and Metabolism, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA.

The preparation of these articles was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the articles. Changes resulting from comments received were made by the authors on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, 0754, New Zealand

    Lesley J. Scott & Katherine A. Lyseng-Williamson

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley J. Scott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott, L.J., Lyseng-Williamson, K.A. Linagliptin: a guide to its use in type 2 diabetes mellitus. Drugs Ther Perspect 28, 1–5 (2012). https://doi.org/10.2165/11208000-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11208000-000000000-00000

Keywords

Search

Navigation